与糖相关的二甲基二甲基碳酸衍生物:一种新型的抗癌药物
Mohammad Najlah1, Niamh McCallum1, Ana Maria Pereira1
1Pharmaceutical Research Group, School of Allied Health, Faculty of Health, Education, Medicine and Social Care, Anglia Ruskin University, Bishops Hall Lane, Chelmsford CM1 1SQ, UK.
International journal of molecular sciences
|June 26, 2025
概括
新型糖化物链接的代谢物二硫 (DSF) 代谢物二甲基二甲酸盐 (DDC) 的前药物通过形成细胞毒性铜复合体,显示出增强的稳定性,溶解性和强大的抗癌活性. 这些发现表明,改善癌症治疗的潜力很大.
科学领域:
- 药用化学 医学化学
- 药物发现 药物发现 药物发现
- 癌症治疗方法 癌症治疗方法
背景情况:
- 迪苏尔菲拉姆 (DSF) 是一种抗酒精药物,其代谢物二甲基二甲基二甲酸盐 (DDC) 介导的抗癌性质.
- DDC形成了向癌症干细胞的细胞毒性铜复合体,但其临床使用受到溶解性差和快速新陈代谢的阻碍.
研究的目的:
- 开发新的糖结合的DDC前药物,以提高稳定性,溶解性和瘤选择性激活.
- 为了评估这些修改后的DDC前药的抗癌潜力.
主要方法:
- 糖结合的DDC衍生物的合成和表征,这些DDC衍生物具有硫糖结.
- 对结直肠,乳腺,肺癌和脑癌细胞系的血清稳定性和体外细胞毒性的评估.
- 评估活性铜 (II) bis (N,N-二甲基二甲酸盐) (Cu (DDC) 2) 复合物的形成.
主要成果:
- 合成的糖化物-DDC前药物表现出增强的血清稳定性和改善的溶解性.
- 复合铜糖-DDC预药在体外表现出各种癌症细胞系中显著的细胞毒性.
- 硫糖酸链接有效地屏蔽了DDC部分,同时保留了金属化能力.
结论:
- 糖结合的DDC代表了开发稳定,铜激活的癌症治疗前药的有希望的策略.
- 这些新型前药具有改善药理动力学特征和增强治疗疗效的潜力.
- 需要进一步的体内研究来确认它们的临床相关性和治疗潜力.
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Oral Hypoglycemic Agents: Sulfonylureas
353
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
353
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
276
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
276


